1.82
-0.065(-3.46%)
Currency In USD
Previous Close | 1.88 |
Open | 1.89 |
Day High | 1.92 |
Day Low | 1.79 |
52-Week High | 7.48 |
52-Week Low | 1.15 |
Volume | 3M |
Average Volume | 4.66M |
Market Cap | 287.45M |
PE | -3.86 |
EPS | -0.47 |
Moving Average 50 Days | 2.33 |
Moving Average 200 Days | 3.16 |
Change | -0.07 |
If you invested $1000 in Humacyte, Inc. (HUMA) since IPO date, it would be worth $187.69 as of August 18, 2025 at a share price of $1.815. Whereas If you bought $1000 worth of Humacyte, Inc. (HUMA) shares 3 years ago, it would be worth $387.82 as of August 18, 2025 at a share price of $1.815.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Humacyte to Present Second Quarter Financial Results and Provide Corporate Update on August 11, 2025
GlobeNewswire Inc.
Aug 07, 2025 12:00 PM GMT
DURHAM, N.C., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, will release its financial results fo
Humacyte Announces First Symvess™ Sale to Military Treatment Facility
GlobeNewswire Inc.
Jul 23, 2025 12:00 PM GMT
Sale follows recent Electronic Catalog (ECAT) listing approval by U.S. Defense Logistics Agency Symvess now available to U.S. Department of Defense and U.S. Department of Veterans Affairs facilities DURHAM, N.C., July 23, 2025 (GLOBE NEWSWIRE) -- H
Humacyte announces Symvess™ ECAT Approval from U.S. Defense Logistics Agency
GlobeNewswire Inc.
Jul 08, 2025 12:00 PM GMT
Electronic Catalog listing approval makes Symvess available to healthcare professionals at U.S. Department of Defense and U.S. Department of Veterans Affairs facilitiesDURHAM, N.C., July 08, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a